

UNITED STATES BANKRUPTCY COURT
 _____ DISTRICT OF DELAWARE

In Re. INVIVO THERAPEUTICS CORPORATION

§
§
§
§

Debtor(s)

Case No. 24-10137Lead Case No. 24-10137☒ Jointly Administered**Monthly Operating Report**

Chapter 11

Reporting Period Ended: 02/29/2024Petition Date: 02/01/2024Months Pending: 1Industry Classification:

5	4	1	7
---	---	---	---

Reporting Method:

Accrual Basis ☒Cash Basis ☐

Debtor's Full-Time Employees (current):

3

Debtor's Full-Time Employees (as of date of order for relief):

3**Supporting Documentation** (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

- ☒ Statement of cash receipts and disbursements
- ☒ Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit
- ☒ Statement of operations (profit or loss statement)
- ☐ Accounts receivable aging
- ☐ Postpetition liabilities aging
- ☐ Statement of capital assets
- ☐ Schedule of payments to professionals
- ☐ Schedule of payments to insiders
- ☒ All bank statements and bank reconciliations for the reporting period
- ☐ Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Joshua B. Brooks

Signature of Responsible Party

03/21/2024

Date

Landis Rath & Cobb LLP

Printed Name of Responsible Party

919 N. Market St., Ste. 1800, Wilmington, DE 19801
Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

Part 1: Cash Receipts and Disbursements	Current Month	Cumulative
a. Cash balance beginning of month	\$5,351,157	
b. Total receipts (net of transfers between accounts)	\$25,829	\$25,829
c. Total disbursements (net of transfers between accounts)	\$193,007	\$193,007
d. Cash balance end of month (a+b-c)	\$5,183,979	
e. Disbursements made by third party for the benefit of the estate	\$0	\$0
f. Total disbursements for quarterly fee calculation (c+e)	\$193,007	\$193,007

Part 2: Asset and Liability Status (Not generally applicable to Individual Debtors. See Instructions.)	Current Month
a. Accounts receivable (total net of allowance)	\$0
b. Accounts receivable over 90 days outstanding (net of allowance)	\$0
c. Inventory (Book <input checked="" type="radio"/> Market <input type="radio"/> Other <input type="radio"/> (attach explanation))	\$0
d. Total current assets	\$6,695,412
e. Total assets	\$6,752,230
f. Postpetition payables (excluding taxes)	\$460,633
g. Postpetition payables past due (excluding taxes)	\$0
h. Postpetition taxes payable	\$0
i. Postpetition taxes past due	\$0
j. Total postpetition debt (f+h)	\$460,633
k. Prepetition secured debt	\$0
l. Prepetition priority debt	\$0
m. Prepetition unsecured debt	\$171,926
n. Total liabilities (debt) (j+k+l+m)	\$632,559
o. Ending equity/net worth (e-n)	\$6,119,671

Part 3: Assets Sold or Transferred	Current Month	Cumulative
a. Total cash sales price for assets sold/transferred outside the ordinary course of business	\$0	\$0
b. Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business	\$0	\$0
c. Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)	\$0	\$0

Part 4: Income Statement (Statement of Operations) (Not generally applicable to Individual Debtors. See Instructions.)	Current Month	Cumulative
a. Gross income/sales (net of returns and allowances)	\$0	
b. Cost of goods sold (inclusive of depreciation, if applicable)	\$0	
c. Gross profit (a-b)	\$0	
d. Selling expenses	\$0	
e. General and administrative expenses	\$667,713	
f. Other expenses	\$59,860	
g. Depreciation and/or amortization (not included in 4b)	\$416	
h. Interest	\$14,951	
i. Taxes (local, state, and federal)	\$0	
j. Reorganization items	\$0	
k. Profit (loss)	\$-713,038	\$-713,038

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

Part 5: Professional Fees and Expenses

			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative	
a.	Debtor's professional fees & expenses (bankruptcy) <i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						
	vii						
	viii						
	ix						
	x						
	xi						
	xii						
	xiii						
	xiv						
	xv						
	xvi						
	xvii						
	xviii						
	xix						
	xx						
	xxi						
	xxii						
	xxiii						
	xxiv						
	xxv						
	xxvi						
	xxvii						
xxviii							
xxix							
xxx							
xxxi							
xxxii							
xxxiii							
xxxiv							
xxxv							
xxxvi							

4

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

	lxxix						
	lxxx						
	lxxxi						
	lxxxii						
	lxxxiii						
	lxxxiv						
	lxxxv						
	lxxxvi						
	lxxxvii						
	lxxxviii						
	lxxxix						
	xc						
	xc i						
	xc ii						
	xc iii						
	xc iv						
	xc v						
	xc vi						
	xc vii						
	xc viii						
	xc ix						
	c						
	ci						

b.			Approved Current Month	Approved Cumulative	Paid Current Month	Paid Cumulative
	Debtor's professional fees & expenses (nonbankruptcy) <i>Aggregate Total</i>					
	<i>Itemized Breakdown by Firm</i>					
	Firm Name	Role				
	i					
	ii					
	iii					
	iv					
	v					
	vi					
	vii					
	viii					
	ix					
	x					
	xi					
	xii					
	xiii					
	xiv					

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xliv						
l						
li						
lii						
liii						
liv						
lv						
lvi						

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						
xc i						
xcii						
xciii						
xciv						
xcv						
xcvi						
xcvii						
xcviii						

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

	xcix						
	c						
c.	All professional fees and expenses (debtor & committees)						

Part 6: Postpetition Taxes**Current Month****Cumulative**

a.	Postpetition income taxes accrued (local, state, and federal)	\$0	\$0
b.	Postpetition income taxes paid (local, state, and federal)	\$0	\$0
c.	Postpetition employer payroll taxes accrued	\$0	\$0
d.	Postpetition employer payroll taxes paid	\$12,246	\$0
e.	Postpetition property taxes paid	\$0	\$0
f.	Postpetition other taxes accrued (local, state, and federal)	\$0	\$0
g.	Postpetition other taxes paid (local, state, and federal)	\$470	\$0

Part 7: Questionnaire - During this reporting period:

- a. Were any payments made on prepetition debt? (if yes, see Instructions) Yes ☐ No ☒
- b. Were any payments made outside the ordinary course of business without court approval? (if yes, see Instructions) Yes ☐ No ☒
- c. Were any payments made to or on behalf of insiders? Yes ☐ No ☒
- d. Are you current on postpetition tax return filings? Yes ☒ No ☐
- e. Are you current on postpetition estimated tax payments? Yes ☒ No ☐
- f. Were all trust fund taxes remitted on a current basis? Yes ☒ No ☐
- g. Was there any postpetition borrowing, other than trade credit? (if yes, see Instructions) Yes ☐ No ☒
- h. Were all payments made to or on behalf of professionals approved by the court? Yes ☐ No ☐ N/A ☒
- i. Do you have:
- Worker's compensation insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- Casualty/property insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- General liability insurance? Yes ☒ No ☐
- If yes, are your premiums current? Yes ☒ No ☐ N/A ☐ (if no, see Instructions)
- j. Has a plan of reorganization been filed with the court? Yes ☐ No ☒
- k. Has a disclosure statement been filed with the court? Yes ☐ No ☒
- l. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137

Part 8: Individual Chapter 11 Debtors (Only)

- | | | |
|--|-------|-----|
| a. Gross income (receipts) from salary and wages | _____ | \$0 |
| b. Gross income (receipts) from self-employment | _____ | \$0 |
| c. Gross income from all other sources | _____ | \$0 |
| d. Total income in the reporting period (a+b+c) | _____ | \$0 |
| e. Payroll deductions | _____ | \$0 |
| f. Self-employment related expenses | _____ | \$0 |
| g. Living expenses | _____ | \$0 |
| h. All other expenses | _____ | \$0 |
| i. Total expenses in the reporting period (e+f+g+h) | _____ | \$0 |
| j. Difference between total income and total expenses (d-i) | _____ | \$0 |
| k. List the total amount of all postpetition debts that are past due | _____ | \$0 |
- l. Are you required to pay any Domestic Support Obligations as defined by 11 U.S.C § 101(14A)? Yes ☐ No ☒
- m. If yes, have you made all Domestic Support Obligation payments? Yes ☐ No ☐ N/A ☒

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106, and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor's progress through the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed to perform the trustee's or examiner's duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I have been authorized to sign this report on behalf of the estate.

/s/ Richard Christopher

Signature of Responsible Party

Chief Financial Officer

Title

InVivo Therapeutics Corporation


Printed Name of Responsible Party

03/21/2024


Date

Debtor's Name INVIVO THERAPEUTICS CORPORATION


Case No. 24-10137




PageOnePartOne



PageOnePartTwo



PageTwoPartOne



PageTwoPartTwo

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137



Bankruptcy1to50



Bankruptcy51to100




NonBankruptcy1to50




NonBankruptcy51to100

Debtor's Name INVIVO THERAPEUTICS CORPORATION

Case No. 24-10137



PageThree



PageFour



Statement of cash receipts disbursements

February
2024

Operating Disbursements

Payroll, benefits and related taxes	\$	189,287
Severance		-
Consulting		-
Clinical Trial Costs		-
Rent		383
Investor Relations		-
Legal Fees		-
Audit and Tax Fees		-
Board of Directors Fees		-
Dues and Subscriptions		147
Insurance		-
Software		-
Mailing and Shipping		-
Telephone		225
Parking		-
Travel		-
Meals and Entertainment		-
Payroll processing fees		949
Office supplies		402
Bank fees		1,144
Miscellaneous expense		-
Taxes - Franchise		470
Total Operating Disbursements		193,007

Process Related Disbursements

<u>Debtor's Professionals</u>		
Landis Rath & Cobb		-
Sonoran		-
SSG		-
Wilmer-Hale		-
Claims agent - KCC		-
Total Debtor's Professionals		-
<u>Additional Professional/Costs</u>		
Committee Professionals		-
UST Fees		-
Total Process Related Disbursements		-

Total Disbursements	\$	193,007
Beginning Cash	\$	5,351,157
Interest		25,590
Collections/Refunds		239
Total Disbursements		(193,007)
Ending Cash	\$	5,183,979

0



Balance Sheet

	<u>2/29/24</u>
ASSETS:	
Current assets:	
Cash and cash equivalents	\$ 5,183,979
Prepaid expenses and other current assets	1,511,433
Total current assets	<u>6,695,412</u>
PP&E, net	6,818
Restricted cash - non current	50,000
Total assets	<u><u>\$ 6,752,230</u></u>
Current liabilities:	
Accounts payable	392,672
Accrued expenses	239,887
Total current liabilities	<u>632,559</u>
Other liabilities	-
Total liabilities	<u>632,559</u>
Stockholders' equity:	
Total stockholders' equity	6,119,671
Total liabilities and stockholders' equity	<u><u>\$ 6,752,230</u></u>
	-



Statement of Operations

	February 2024
Operating Expenses:	
Research and development	\$ 59,860
General and administrative	668,129
Total operating expenses	<u>727,989</u>
Operating loss	<u>(727,989)</u>
Other income/(expense):	
Other income	14,951
Other income/(expense), net	<u>14,951</u>
Net loss	<u><u>\$ (713,038)</u></u>

-

InVivo Therapeutics
Cash Reconciliation
02/29/24

<u>Account Type</u>	<u>Acct #</u>	<u>Total Per Bank Statement</u>	<u>Uncashed Checks</u>	<u>Acct Transfer In Transit</u>	<u>Other Assets</u>		<u>Cash Balance</u>
					<u>Interest Receivable</u>	<u>Restricted Cash</u>	
Operating	XXXXXX4583	\$ 250,000	\$ (1,734)	\$ -	\$ -	\$ -	\$ 248,267
Sweep	XXXXXX0747	4,948,190	-	(12,478)	-	-	4,935,712
Investment	XXXXXX1145	3,695	-	-	(3,695)	-	-
Security Deposit	XXXXXX0116	50,000	-	-	-	(50,000)	-
Total		\$ 5,251,886	\$ (1,734)	\$ (12,478)	\$ (3,695)	\$ (50,000)	\$ 5,183,979

3003 Tasman Drive, Santa Clara, CA 95054

February 2024

Reporting Activity 02/01 - 02/29





Page 1 of 8

ADDRESS SERVICE REQUESTED

>003800 5246670 0001 092196 10Z

INVIVO THERAPEUTICS CORPORATION
1500 DISTRICT AVENUE
BURLINGTON, MA 01803

Managing Your Accounts

	Phone:	(408) 654-4636
	Toll-Free:	(800) 774-7390
	Email:	clientsupport@svb.com
	Online:	www.svb.com

Summary of Accounts

Account Type	Account Number	Ending Balance
Analysis Checking	XXXXXXX4583	\$250,000.40
Total Balance		\$250,000.40

Analysis Checking - XXXXXX4583

Account Summary

Date	Description	
02/01/2024	Beginning Balance	\$250,000.42
02/29/2024	Ending Balance	\$250,000.40
	Total debits this period	\$3,369,329.07
	Total credits this period	\$3,369,329.05
	Service Charge	\$0.00

Account Activity

Transaction Date	Description	Debits	Credits	Balance
02/01/2024	Beginning Balance			\$250,000.42
02/01/2024	CHECK #16903	-\$540.00	\$0.00	\$249,460.42
02/01/2024	CASH SWEEP REDEMPTION	\$0.00	\$539.58	\$250,000.00
02/02/2024	CHECK #16921	-\$8,925.00	\$0.00	\$241,075.00
02/02/2024	CASH SWEEP REDEMPTION	\$0.00	\$8,925.00	\$250,000.00
02/05/2024	DEPOSIT	\$0.00	\$238.74	\$250,238.74
02/05/2024	WAGeworks FSA RECEIVABLE INV6139888 INVIVO THERAPEUTICS HO	-\$15.98	\$0.00	\$250,222.76
02/05/2024	CHECK #16919	-\$722.40	\$0.00	\$249,500.36
02/05/2024	CASH SWEEP REDEMPTION	\$0.00	\$738.38	\$250,238.74
02/06/2024	CHECK #16902	-\$81.12	\$0.00	\$250,157.62
02/06/2024	CASH SWEEP PURCHASE	-\$157.62	\$0.00	\$250,000.00
02/07/2024	CHECK #16916	-\$212.42	\$0.00	\$249,787.58

CHECKS OUTSTANDING									CHECKBOOK RECONCILIATION		
DATE OR #	AMOUNT		DATE OR #	AMOUNT		DATE OR #	AMOUNT				
									ENTER BALANCE THIS STATEMENT	\$	
									ADD		
									RECENT DEPOSITS (NOT CREDITED ON THIS STATEMENT)	\$	
									SUBTOTAL	\$	
									SUBTRACT TOTAL ITEMS OUTSTANDING	\$	
BALANCE should agree with your checkbook balance after deducting charges and adding credits not shown in your checkbook but included on this statement as follows: Interest-ADD Overdraft-DEDUCT Automatic Payment-DEDUCT Automatic Advance-ADD Service Charge-DEDUCT									BALANCE	\$	

PLEASE REPORT ANY ERRORS OR OMISSIONS PROMPTLY TO US. ERRORS OR OMISSIONS THAT ARE REPORTED WITHIN THE FIRST 30 DAYS FROM THE DATE OF THE LAST STATEMENT CYCLE ARE USUALLY RESOLVED MUCH MORE QUICKLY THAN DATED REQUESTS. As a fraud prevention measure, you need to review your statements and report unauthorized use or errors to us, as explained in more detail below.

If your checkbook and statement do not balance have you:

- ☐ Accounted for bank charges? ☐ Verified additions and subtractions in your checkbook? ☐ Compared canceled checks to check stub? ☐ Compared deposit amounts on statement to your checkbook?

Any charges for imprinted checks include state sales tax computed at the current rate, when applicable. You can call (800) 774-7390 to request an item or substitute check, or a legible copy. We will without charge provide at least two items (or substitute checks or legible copies) upon request, with respect to each statement.

IN CASE OF ERRORS OR QUESTIONS CONCERNING YOUR ELECTRONIC TRANSFERS
(For Consumer Clients)

Telephone Silicon Valley Bank at (800) 774-7390 or write us at: Silicon Valley Bank, Attn: Client Services, 3003 Tasman Drive, Santa Clara, CA 95054, as soon as you can, if you think your statement or your receipt is wrong or if you need more information about a transfer on the statement or receipt. We must hear from you no later than 60 days after we sent you the FIRST statement on which the error or problem appeared.

- Tell us your name and account number (if any).
- Describe the error or the transfer you are unsure about, and explain as clearly as you can why you believe this is an error or why you need more information.
- Tell us the dollar amount of the suspected error.

We will investigate your complaint and will correct any error promptly. If we take more than 10 business days to do this, we will credit your account for the amount you think is in error, so that you will have the use of the money during the time it takes us to complete our investigation.

For questions about preauthorized transfers, please contact us at (800) 774-7390.

IN CASE OF UNAUTHORIZED USE OF YOUR CHECKS OR ACCOUNTS

You agree to review your statement and to report unauthorized use (checks or other charges that are forged, altered or other unauthorized use) or error immediately. Your deposit agreement sets specific times within which you must report unauthorized use or errors to us. In summary (and subject to special rules that may apply to consumers), if you fail to report unauthorized use or errors to us within 30 days after your statement is available, you may be liable for subsequent unauthorized use by the same wrongdoer. If you fail to report within 60 days, you may also be precluded from asserting the unauthorized use or other error against us. Your statement is deemed "available" when made available in paper or electronic form. Your deposit agreement or Related Agreements may set shorter reporting requirements, such as for ACH services.

FAIR CREDIT REPORTING ACT

We may report information about your account to credit bureaus. Late payments, missed payments, or other defaults on your account may be reflected in your credit report.

February 2024

Reporting Activity 02/01 - 02/29

Page 3 of 8

Analysis Checking - XXXXXX4583 (continued)

Account Activity (continued)

Transaction Date	Description	Debits	Credits	Balance
02/07/2024	CASH SWEEP REDEMPTION	\$0.00	\$212.42	\$250,000.00
02/09/2024	WIRE IN 240209J1Q5040C001137 202404006903;ORG INVIVO THERAP EUTIC;REF 240209B00JRG	\$0.00	\$3,248,231.93	\$3,498,231.93
02/09/2024	IRON MOUNTAIN RECRD MGMT 7667866 INVIVO THERAPEUTICS *C	-\$129.00	\$0.00	\$3,498,102.93
02/09/2024	ADP PAYROLL FEES ADP FEES 395093575277 653523154INVIVO THERAP	-\$423.70	\$0.00	\$3,497,679.23
02/09/2024	ADP PAYROLL FEES ADP FEES 395093575276 653523430INVIVO THERAP	-\$450.00	\$0.00	\$3,497,229.23
02/09/2024	WIRE OUT 240209L1B77D1C001811 202404007403;BNF ADP, LLC.;OBI NET PAY AND TAX - PAYDATE 02.	-\$81,859.92	\$0.00	\$3,415,369.31
02/09/2024	CASH SWEEP PURCHASE	-\$3,165,369.31	\$0.00	\$250,000.00
02/12/2024	CHECK #16918	-\$265.00	\$0.00	\$249,735.00
02/12/2024	CASH SWEEP REDEMPTION	\$0.00	\$265.00	\$250,000.00
02/13/2024	WAGEWORKS FSA RECEIVABLE INV6174072 INVIVO THERAPEUTICS HO	-\$90.00	\$0.00	\$249,910.00
02/13/2024	WAGEWORKS FSA RECEIVABLE INV6176536 INVIVO THERAPEUTICS HO	-\$114.55	\$0.00	\$249,795.45
02/13/2024	CASH SWEEP REDEMPTION	\$0.00	\$204.55	\$250,000.00
02/14/2024	HEALTHEQUITY INC HealthEqui 81795 InVivo Therapeutics Co	-\$504.29	\$0.00	\$249,495.71
02/14/2024	CASH SWEEP REDEMPTION	\$0.00	\$504.29	\$250,000.00
02/15/2024	WIRE OUT 240215L1B77D1C001620 202404605977;BNF CHARLES SCHWA B;OBI PLAN ACCOUNT 6670-8958IN	-\$12,377.88	\$0.00	\$237,622.12
02/15/2024	CASH SWEEP REDEMPTION	\$0.00	\$12,377.88	\$250,000.00
02/20/2024	BASIC BENEFITS PAYMENTS 31987840 170583 INVIVO THERAPEU	-\$47.63	\$0.00	\$249,952.37

03800 524670 045036 090071 0002/0004

February 2024

Reporting Activity 02/01 - 02/29

Page 4 of 8

Analysis Checking - XXXXXX4583 (continued)

Account Activity (continued)

Transaction Date	Description	Debits	Credits	Balance
02/20/2024	WIRE OUT 240510777900 202405107779;BNF SVB CARD OPER ATIONS - ACH PAYMENTS;OBI INVI	-\$603.19	\$0.00	\$249,349.18
02/20/2024	WIRE OUT 240510775200 202405107752;BNF SVB CARD OPER ATIONS- ACH PAYMENTS;OBI INVIV	-\$669.15	\$0.00	\$248,680.03
02/20/2024	CASH SWEEP REDEMPTION	\$0.00	\$1,319.97	\$250,000.00
02/21/2024	ADP PAYROLL FEES ADP FEES 793071119273 654135144INVIVO THERAP	-\$75.00	\$0.00	\$249,925.00
02/21/2024	CHECK #16923	-\$125.10	\$0.00	\$249,799.90
02/21/2024	CASH SWEEP REDEMPTION	\$0.00	\$200.10	\$250,000.00
02/23/2024	WAGEWORKS RECEIVABLE INV6102559 INVIVO THERAPEUTICS HO	-\$24.00	\$0.00	\$249,976.00
02/23/2024	WIRE OUT 240223L1B77D1C001065 202405404986;BNF ADP, LLC.;OBI NET PAY AND TAX - PAYDATE 2.2	-\$80,671.42	\$0.00	\$169,304.58
02/23/2024	CHECK #16922	-\$11.85	\$0.00	\$169,292.73
02/23/2024	CHECK #16899	-\$780.00	\$0.00	\$168,512.73
02/23/2024	CASH SWEEP REDEMPTION	\$0.00	\$81,487.27	\$250,000.00
02/26/2024	WAGEWORKS RECEIVABLE INV6116154 INVIVO THERAPEUTICS HO	-\$185.00	\$0.00	\$249,815.00
02/26/2024	ANALYSIS SERVICE CHARGE	-\$414.00	\$0.00	\$249,401.00
02/26/2024	CHECK #16924	-\$57.50	\$0.00	\$249,343.50
02/26/2024	CASH SWEEP REDEMPTION	\$0.00	\$656.50	\$250,000.00
02/27/2024	WAGEWORKS FSA RECEIVABLE INV6230888 INVIVO THERAPEUTICS HO	-\$192.31	\$0.00	\$249,807.69
02/27/2024	CASH SWEEP REDEMPTION	\$0.00	\$192.31	\$250,000.00
02/28/2024	WAGEWORKS FSA RECEIVABLE INV6241011 INVIVO THERAPEUTICS HO	-\$756.50	\$0.00	\$249,243.50
02/28/2024	CASH SWEEP REDEMPTION	\$0.00	\$756.50	\$250,000.00

February 2024

Reporting Activity 02/01 - 02/29

Page 5 of 8

Analysis Checking - XXXXXX4583 (continued)

Account Activity (continued)

Transaction Date	Description	Debits	Credits	Balance
02/29/2024	WIRE OUT 240229L1B77D1C002304 202406009013;BNF CHARLES SCHWA B;OBI PLAN ACCOUNT 6670-8958IN	-\$12,377.88	\$0.00	\$237,622.12
02/29/2024	CHECK #16925	-\$100.35	\$0.00	\$237,521.77
02/29/2024	CASH SWEEP REDEMPTION	\$0.00	\$12,478.23	\$250,000.00
02/29/2024	INT TRANSFER FROM 3301090116	\$0.00	\$0.40	\$250,000.40
02/29/2024	Ending Balance			\$250,000.40

Checks Cleared

Check Date	Check Number	Check Amount	Check Date	Check Number	Check Amount
02/23/2024	16899	\$780.00	02/06/2024	16902*	\$81.12
02/01/2024	16903	\$540.00	02/07/2024	16916*	\$212.42
02/12/2024	16918*	\$265.00	02/05/2024	16919	\$722.40
02/02/2024	16921*	\$8,925.00	02/23/2024	16922	\$11.85
02/21/2024	16923	\$125.10	02/26/2024	16924	\$57.50
02/29/2024	16925	\$100.35			

* Indicates skipped check number

February 2024

Reporting Activity 02/01 - 02/29

Page 6 of 8

THIS PAGE LEFT INTENTIONALLY BLANK

February 2024

Reporting Activity 02/01 - 02/29

Page 7 of 8

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Distance Advisory Associates LLC
Seven Hundred eighty and 00/100

Amount: \$780.00

Check #: 16899

Date: 02/23/2024

Amount in Words: Seven Hundred eighty and 00/100

Signature: [Signature]

Amount in Numbers: 780.00

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: XEL Systems, Inc
Eighty one and 12/100

Amount: \$81.12

Check #: 16902

Date: 02/06/2024

Amount in Words: Eighty one and 12/100

Signature: [Signature]

Amount in Numbers: 81.12

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Keri Terry (US)
Two hundred forty and 00/100

Amount: \$540.00

Check #: 16903

Date: 02/01/2024

Amount in Words: Two hundred forty and 00/100

Signature: [Signature]

Amount in Numbers: 540.00

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: A730
Two hundred twenty two and 42/100

Amount: \$212.42

Check #: 16916

Date: 02/07/2024

Amount in Words: Two hundred twenty two and 42/100

Signature: [Signature]

Amount in Numbers: 212.42

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Corporate Things LLC
Two hundred sixty five and 00/100

Amount: \$265.00

Check #: 16918

Date: 02/12/2024

Amount in Words: Two hundred sixty five and 00/100

Signature: [Signature]

Amount in Numbers: 265.00

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Modern Communications, Inc
Seven hundred twenty two and 40/100

Amount: \$722.40

Check #: 16919

Date: 02/05/2024

Amount in Words: Seven hundred twenty two and 40/100

Signature: [Signature]

Amount in Numbers: 722.40

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Topgun Merch LLC
Eight thousand nine hundred twenty five and 00/100

Amount: \$8,925.00

Check #: 16921

Date: 02/02/2024

Amount in Words: Eight thousand nine hundred twenty five and 00/100

Signature: [Signature]

Amount in Numbers: 8925.00

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: HealthCare Employer Services
Eleven and 85/100

Amount: \$11.85

Check #: 16922

Date: 02/23/2024

Amount in Words: Eleven and 85/100

Signature: [Signature]

Amount in Numbers: 11.85

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Verdon
One hundred twenty five and 10/100

Amount: \$125.10

Check #: 16923

Date: 02/21/2024

Amount in Words: One hundred twenty five and 10/100

Signature: [Signature]

Amount in Numbers: 125.10

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Valon Service Firm
Fifty seven and 50/100

Amount: \$57.50

Check #: 16924

Date: 02/26/2024

Amount in Words: Fifty seven and 50/100

Signature: [Signature]

Amount in Numbers: 57.50

INVO THERAPEUTICS CORPORATION
ONE HUNTER DRIVE, SUITE 100
CARMEL, CA 96301

Pay to the order of: Volux, Inc
One hundred and 05/100

Amount: \$100.35

Check #: 16925

Date: 02/29/2024

Amount in Words: One hundred and 05/100

Signature: [Signature]

Amount in Numbers: 100.35

THIS PAGE LEFT INTENTIONALLY BLANK



3003 Tasman Drive, Santa Clara, CA 95054

February 2024

Reporting Activity 02/01 - 02/29

Page 1 of 4

ADDRESS SERVICE REQUESTED

INVIVO THERAPEUTICS CORPORATION
1500 DISTRICT AVENUE
BURLINGTON MA 01803


DDA #: XXXXXX4583 Target Balance: \$250,000.00

Managing Your Accounts

- Phone: (408) 654-4636
- Toll-Free: (800) 774-7390
- Email: clientsupport@svb.com
- Online: www.svb.com

Messages/Notifications

Month-End Allocation %



SVB Cash Sweep Summary - Account XXXXXX0747

Fund Name	CUSIP	Ticker	Avg. Monthly Balance	Month-End Position	Net Monthly Income Earned*	Avg. Gross Yield**
Western Asset Inst US Treas Res/Inv	52470G684	LTRXX	\$1,914,289.09	\$2,474,095.23	\$7,362.47	5.150%
BlackRock Liquidity:T-Fund Admin	09248U676	BTAXX	\$1,914,287.73	\$2,474,095.23	\$7,282.80	5.100%
Totals				\$4,948,190.46	\$14,645.27	

* Net Monthly Income Earned represents dividends earned in the current month, which are paid on the first day of the following month, less bank sweep fees.
** Avg. Gross Yield is the annualized average 30 day yield gross of any bank sweep fees.

MONEY MARKET MUTUAL FUND INVESTMENTS ARE:
NOT A DEPOSIT - NOT FDIC INSURED - NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY - NOT GUARANTEED BY THE BANK - MAY LOSE VALUE

**February 2024**

Reporting Activity 02/01 - 02/29

Page 2 of 4

SVB Cash Sweep Activity - Western Asset Inst US Treas Res/Inv

Date	Transaction Description	Transaction Amount	Price	Investment Balance
02/01/2024	Dividend Reinvest	\$5,650.45	\$1.00	
02/01/2024	Fee Charged	(\$339.03)	\$1.00	
02/01/2024	Redemption	(\$36,114.16)	\$1.00	\$945,541.47
02/02/2024	Redemption	(\$289.62)	\$1.00	\$945,251.85
02/05/2024	Redemption	(\$4,462.50)	\$1.00	\$940,789.35
02/06/2024	Redemption	(\$369.19)	\$1.00	\$940,420.16
02/07/2024	Purchase	\$78.81	\$1.00	\$940,498.97
02/08/2024	Redemption	(\$106.21)	\$1.00	\$940,392.76
02/12/2024	Purchase	\$1,582,684.65	\$1.00	\$2,523,077.41
02/13/2024	Redemption	(\$132.50)	\$1.00	\$2,522,944.91
02/14/2024	Redemption	(\$102.27)	\$1.00	\$2,522,842.64
02/15/2024	Redemption	(\$252.15)	\$1.00	\$2,522,590.49
02/16/2024	Redemption	(\$6,188.94)	\$1.00	\$2,516,401.55
02/21/2024	Redemption	(\$659.98)	\$1.00	\$2,515,741.57
02/22/2024	Redemption	(\$100.05)	\$1.00	\$2,515,641.52
02/26/2024	Redemption	(\$40,743.63)	\$1.00	\$2,474,897.89
02/27/2024	Redemption	(\$328.26)	\$1.00	\$2,474,569.63
02/28/2024	Redemption	(\$96.15)	\$1.00	\$2,474,473.48
02/29/2024	Redemption	(\$378.25)	\$1.00	\$2,474,095.23

MONEY MARKET MUTUAL FUND INVESTMENTS ARE:**NOT A DEPOSIT - NOT FDIC INSURED - NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY - NOT GUARANTEED BY THE BANK - MAY LOSE VALUE**

**February 2024**

Reporting Activity 02/01 - 02/29

Page 3 of 4

SVB Cash Sweep Activity - BlackRock Liquidity:T-Fund Admin

Date	Transaction Description	Transaction Amount	Price	Investment Balance
02/01/2024	Redemption	(\$36,114.18)	\$1.00	
02/01/2024	Dividend Reinvest	\$5,608.27	\$1.00	
02/01/2024	Fee Charged	(\$336.50)	\$1.00	\$945,501.81
02/02/2024	Redemption	(\$249.96)	\$1.00	\$945,251.85
02/05/2024	Redemption	(\$4,462.50)	\$1.00	\$940,789.35
02/06/2024	Redemption	(\$369.19)	\$1.00	\$940,420.16
02/07/2024	Purchase	\$78.81	\$1.00	\$940,498.97
02/08/2024	Redemption	(\$106.21)	\$1.00	\$940,392.76
02/12/2024	Purchase	\$1,582,684.66	\$1.00	\$2,523,077.42
02/13/2024	Redemption	(\$132.50)	\$1.00	\$2,522,944.92
02/14/2024	Redemption	(\$102.28)	\$1.00	\$2,522,842.64
02/15/2024	Redemption	(\$252.14)	\$1.00	\$2,522,590.50
02/16/2024	Redemption	(\$6,188.94)	\$1.00	\$2,516,401.56
02/21/2024	Redemption	(\$659.99)	\$1.00	\$2,515,741.57
02/22/2024	Redemption	(\$100.05)	\$1.00	\$2,515,641.52
02/26/2024	Redemption	(\$40,743.64)	\$1.00	\$2,474,897.88
02/27/2024	Redemption	(\$328.24)	\$1.00	\$2,474,569.64
02/28/2024	Redemption	(\$96.16)	\$1.00	\$2,474,473.48
02/29/2024	Redemption	(\$378.25)	\$1.00	\$2,474,095.23

MONEY MARKET MUTUAL FUND INVESTMENTS ARE:**NOT A DEPOSIT - NOT FDIC INSURED - NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY - NOT GUARANTEED BY THE BANK - MAY LOSE VALUE**



February 2024

Reporting Activity 02/01 - 02/29

Page 4 of 4

THIS PAGE LEFT INTENTIONALLY BLANK.

**MONEY MARKET MUTUAL FUND INVESTMENTS ARE:
NOT A DEPOSIT - NOT FDIC INSURED - NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY - NOT GUARANTEED BY THE BANK - MAY LOSE VALUE**



SVB-Standard Statement Package

██████████ 1145-InVivo Therapeutics (43924)

Month End (M2 Y2024)

02/01/2024 - 02/29/2024

Dated: 03/05/2024

Locked Down

Table of Contents

Dated: 03/05/2024

<u>SVB Account Summary (██████ 1145-InVivo Therapeutics (43924))</u>	1
<u>GAAP FX Financials (██████ 1145-InVivo Therapeutics (43924))</u>	2
<u>GAAP FX Trial Balance (██████ 1145-InVivo Therapeutics (43924))</u>	3
<u>GAAP FX Entry Summary (██████ 1145-InVivo Therapeutics (43924))</u>	4
<u>GAAP Entry Detail (██████ 1145-InVivo Therapeutics (43924))</u>	5
<u>Income Detail (██████ 1145-InVivo Therapeutics (43924))</u>	7
<u>Balance Sheet Classification Report (██████ 1145-InVivo Therapeutics (43924))</u>	8
<u>Transaction Detail (██████ 1145-InVivo Therapeutics (43924))</u>	9
<u>Trading Activity (██████ 1145-InVivo Therapeutics (43924))</u>	10
<u>Roll Forward (██████ 1145-InVivo Therapeutics (43924))</u>	11

SVB Account Summary

Functional Currency: USD 02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

1145-InVivo Therapeutics (43924)

Dated: 03/05/2024

Portfolio Parameters


Beginning Market Value	3,248,286.09	Portfolio Duration	0
Ending Market Value	3,694.72	Portfolio Days to Maturity	0
Net Change	-3,244,591.37	Yield on Cost	0.000%
Average Rating	AAA/Aaa/AAA	Market Yield	0.000%
Number of Holdings	1		

Purchases & Sales Summary

	Purchases	Sales	Maturities
Cash Equivalents (<= 90 days)	-14,333.58	3,248,286.09	0.00
ST Investments (>90 days, <= 365 days)	0.00	0.00	0.00
LT Investments (> 365 days)	0.00	0.00	0.00
Total	-14,333.58	3,248,286.09	0.00

Portfolio Performance


	Actual	Annualized
Income Return	0.114%	1.442%
Price Return	0.000%	0.000%
Total Return	0.114%	1.442%




	Month to Date 2/1/24 - 2/29/24	Quarter to Date 1/1/24 - 2/29/24	Year to Date 1/1/24 - 2/29/24	Prior Month 1/1/24 - 1/31/24	Prior Year 1/1/23 - 12/31/23
Total Return	0.114%	0.558%	0.558%	0.443%	5.040%
Index Return	0.410%	0.839%	0.839%	0.427%	5.015%
Excess Return	-0.296%	-0.281%	-0.281%	0.016%	0.026%

Index: ICE BofA 3-Month US Treasury Bill Index (G001)


SECTOR ALLOCATION



MATURITY BREAKDOWN



CREDIT QUALITY ALLOCATION



GAAP FX Financials

02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

1145-InVivo Therapeutics (43924)

Dated: 03/05/2024

Balance Sheet

1145-InVivo Therapeutics		
As of:	01/31/2024	02/29/2024
Book Value	3,248,286.09	3,694.72
Accrued Balance	0.00	0.00
Book Value + Accrued	3,248,286.09	3,694.72
Net FX Unrealized Accrued Gain/Loss	0.00	0.00
Net FX Unrealized Carrying Value Security	0.00	0.00
Gain/Loss		
Net Market Unrealized Carrying Value	0.00	0.00
Gain/Loss		
Carrying Value and Accrued	3,248,286.09	3,694.72

Income Statement

1145-InVivo Therapeutics		
	Begin Date	02/01/2024
	End Date	02/29/2024
Net Amortization/Accretion Income		0.00
Interest Income	3,694.72	
Dividend Income	0.00	
Foreign Tax Withheld Expense	0.00	
Misc Income	0.00	
Net FX Allowance Expense	0.00	
Net Market Allowance Expense	0.00	
Income Subtotal		3,694.72
Net FX Realized Gain/Loss	0.00	
Net Market Realized Gain/Loss	0.00	
Net Total Holding Gain/Loss	0.00	
Total Impairment Loss	0.00	
Net Total Gain/Loss		0.00
Expense	-54.16	
Net Income		3,640.56
Transfers In/Out		-3,248,231.93
Change in FX Unrealized Gain/Loss		0.00
Change in Market Unrealized Gain/Loss		0.00

Statement of Cash Flows

1145-InVivo Therapeutics		
	Begin Date	02/01/2024
	End Date	02/29/2024
Net Income		3,640.56
Amortization/Accretion on MS	0.00	
Change in Accrued on MS	0.00	
Net Gain/Loss on MS	0.00	
Change in Unrealized G/L on CE	0.00	
Subtotal		0.00
Purchase of MS	0.00	
Purchased Accrued of MS	0.00	
Sales of MS	0.00	
Sold Accrued of MS	0.00	
Maturities of MS	0.00	
Net Purchases/Sales		0.00
Transfers of Cash & CE		-3,248,231.93
Total Change in Cash & CE		-3,244,591.37
Beginning Cash & CE		3,248,286.09
Ending Cash & CE		3,694.72

GAAP FX Trial Balance

1145-InVivo Therapeutics (43924)

02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

Dated: 03/05/2024

Asset

GL Account Description	Balance Type	Beginning Balance	Activity	Ending Balance
Accrued Interest	Asset	0.00	0.00	0.00
Cash	Asset	0.00	0.00	0.00
CE Book Value	Asset	3,233,952.51	-3,233,952.51	0.00
Receivable	Asset	14,333.58	-10,638.86	3,694.72
---	---	3,248,286.09	-3,244,591.37	3,694.72

Income & Expense

GL Account Description	Balance Type	Beginning Balance	Activity	Ending Balance
Interest Income	Income	14,333.58	3,694.72	18,028.30
Miscellaneous Expense	Expense	-125.00	-54.16	-179.16
---	---	14,208.58	3,640.56	17,849.14

Other

GL Account Description	Balance Type	Beginning Balance	Activity	Ending Balance
Cash Transfers	Equity	0.00	-3,248,231.93	-3,248,231.93
Prior Year Cash Transfers	Equity	2,500,000.00	0.00	2,500,000.00
Prior Year Income	Equity	734,077.51	0.00	734,077.51
---	---	3,234,077.51	-3,248,231.93	-14,154.42

* Grouped by: Trial Balance Grouping. * Groups Sorted by: Trial Balance Grouping.

GAAP FX Entry Summary

02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

1145-InVivo Therapeutics (43924)

Dated: 03/05/2024

Buy

Activity Type	Currency	GL Account Description	Debit	Credit
Buy	USD	Cash	0.00	14,333.58
Buy	USD	CE Book Value	14,333.58	0.00
Buy	USD	Payable	14,333.58	14,333.58
Buy	USD	---	28,667.16	28,667.16

Cash Transfer

Activity Type	Currency	GL Account Description	Debit	Credit
Cash Transfer	USD	Cash	902,991.83	4,151,223.76
Cash Transfer	USD	Cash Transfers	4,151,223.76	902,991.83
Cash Transfer	USD	Payable	4,151,223.76	4,151,223.76
Cash Transfer	USD	Receivable	902,991.83	902,991.83
Cash Transfer	USD	---	10,108,431.18	10,108,431.18

Custody Fee

Activity Type	Currency	GL Account Description	Debit	Credit
Custody Fee	USD	Cash	0.00	54.16
Custody Fee	USD	Miscellaneous Expense	54.16	0.00
Custody Fee	USD	Payable	54.16	54.16
Custody Fee	USD	---	108.32	108.32

Interest Income

Activity Type	Currency	GL Account Description	Debit	Credit
Interest Income	USD	Accrued Interest	3,694.72	0.00
Interest Income	USD	Interest Income	0.00	3,694.72
Interest Income	USD	---	3,694.72	3,694.72

Money Market Funds

Activity Type	Currency	GL Account Description	Debit	Credit
Money Market Funds	USD	Accrued Interest	13,871.59	17,566.31
Money Market Funds	USD	Cash	14,333.58	0.00
Money Market Funds	USD	Interest Income	461.99	461.99
Money Market Funds	USD	Receivable	3,694.72	14,333.58
Money Market Funds	USD	---	32,361.88	32,361.88

Sell

Activity Type	Currency	GL Account Description	Debit	Credit
Sell	USD	Cash	3,248,286.09	0.00
Sell	USD	CE Book Value	0.00	3,248,286.09
Sell	USD	Receivable	3,248,286.09	3,248,286.09
Sell	USD	---	6,496,572.18	6,496,572.18

* Grouped by: Activity Type. * Groups Sorted by: Activity Type.

GAAP Entry Detail

02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

[REDACTED] 145-InVivo Therapeutics (43924)

Dated: 03/05/2024

Buy

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
61747C707	USD	Cash	02/02/2024	Cash	0.00	14,333.58
61747C707	USD	MORG STAN I LQ:GV I	02/02/2024	CE Book Value	14,333.58	0.00
61747C707	USD	Payable	02/02/2024	Payable	14,333.58	14,333.58
61747C707	USD	---	02/02/2024	---	28,667.16	28,667.16

Cash Transfer

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
CCYUSD	USD	Cash	02/09/2024	Cash	902,991.83	4,151,223.76
CCYUSD	USD	Cash	02/09/2024	Cash Transfers	4,151,223.76	902,991.83
CCYUSD	USD	Payable	02/09/2024	Payable	4,151,223.76	4,151,223.76
CCYUSD	USD	Receivable	02/09/2024	Receivable	902,991.83	902,991.83
CCYUSD	USD	---	02/09/2024	---	10,108,431.18	10,108,431.18

Custody Fee

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
CCYUSD	USD	Cash	02/22/2024	Cash	0.00	54.16
CCYUSD	USD	Cash	02/22/2024	Miscellaneous Expense	54.16	0.00
CCYUSD	USD	Payable	02/22/2024	Payable	54.16	54.16
CCYUSD	USD	---	02/22/2024	---	108.32	108.32

Interest Income

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
61747C707	USD	MORG STAN I LQ:GV I	---	Accrued Interest	3,694.72	0.00
61747C707	USD	MORG STAN I LQ:GV I	---	Interest Income	0.00	3,694.72
61747C707	USD	MORG STAN I LQ:GV I	---	---	3,694.72	3,694.72

Money Market Funds

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
61747C707	USD	Cash	02/01/2024	Cash	14,333.58	0.00
61747C707	USD	MORG STAN I LQ:GV I	02/29/2024	Accrued Interest	0.00	3,694.72
61747C707	USD	MORG STAN I LQ:GV I	02/01/2024	Accrued Interest	13,871.59	13,871.59
61747C707	USD	MORG STAN I LQ:GV I	02/29/2024	Interest Income	0.00	0.00
61747C707	USD	MORG STAN I LQ:GV I	02/01/2024	Interest Income	461.99	461.99
61747C707	USD	Receivable	02/01/2024	Receivable	0.00	14,333.58
61747C707	USD	Receivable	02/29/2024	Receivable	3,694.72	0.00
61747C707	USD	---	---	---	32,361.88	32,361.88

Sell

Identifier	Currency	Description	Entry Date	GL Account Description	Debit	Credit
61747C707	USD	Cash	02/09/2024	Cash	3,248,286.09	0.00
61747C707	USD	MORG STAN I LQ:GV I	02/09/2024	CE Book Value	0.00	3,248,286.09
61747C707	USD	Receivable	02/09/2024	Receivable	3,248,286.09	3,248,286.09
61747C707	USD	---	02/09/2024	---	6,496,572.18	6,496,572.18

GAAP Entry Detail

02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

1145-InVivo Therapeutics (43924)

Dated: 03/05/2024

* Grouped by: Activity Type. * Groups Sorted by: Activity Type.

Income Detail

Base Currency: USD 02/01/2024 - 02/29/2024

[Return to Table of Contents](#)
 145-InVivo Therapeutics (43924)

Dated: 03/05/2024

Identifier	Ending Base Current Units	Description	Coupon	Final Maturity	Effective Maturity	Transfers In/Out	Net Realized Gain/Loss	Net Amortization/ Accretion Income	Interest/Dividend Income	Base Expense	Base Net Income	Settle Date
CCYUSD	0.00	Cash	0.000	02/29/2024	02/29/2024	-3,248,231.93	0.00	0.00	0.00	-54.16	-54.16	---
61747C707	0.00	MORG STAN I LQ:GV I	5.220	02/29/2024	02/29/2024	0.00	0.00	0.00	3,694.72	0.00	3,694.72	---
CCYUSD	3,694.72	Receivable	0.000	02/29/2024	02/29/2024	0.00	0.00	0.00	0.00	0.00	0.00	---
---	3,694.72	---	---	02/29/2024	02/29/2024	-3,248,231.93	0.00	0.00	3,694.72	-54.16	3,640.56	---

* Weighted by: Ending Base Market Value + Accrued. * Holdings Displayed by: Lot.

Balance Sheet Classification Report

██████████ 1145-InVivo Therapeutics (43924)

Base Currency: USD As of 02/29/2024

[Return to Table of Contents](#)

Dated: 03/05/2024

CE

Identifier	Description	Base Current Units	Market Sector	Coupon	Effective Maturity	Book Yield	Yield	Base Book Value	Base Net Total Unrealized Gain/Loss	Market Price	Base Accrued Balance	Base Market Value + Accrued
CCYUSD	Receivable	3,694.72	Cash	0.000	02/29/2024	0.000	0.000	3,694.72	0.00	1.0000	0.00	3,694.72
CCYUSD	Receivable	3,694.72	Cash	0.000	02/29/2024	0.000	0.000	3,694.72	0.00	1.0000	0.00	3,694.72

* Grouped by: BS Class 2. * Groups Sorted by: BS Class 2. * Weighted by: Base Market Value + Accrued, except Book Yield by Base Book Value + Accrued. * Holdings Displayed by: Lot.

Transaction Detail

1145-InVivo Therapeutics (43924)

Base Currency: USD 02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

Dated: 03/05/2024

* Does not Lock Down.

Receivable

Entry Date	Settle Date	Transaction Type	Base Current Units	Identifier	Description	Coupon Rate	Final Maturity	Price	Base Amount
02/29/2024	02/29/2024	Money Market Funds	0.00	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	---	3,694.72
02/29/2024	02/29/2024	Money Market Funds	0.00	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	---	3,694.72

Settled

Entry Date	Settle Date	Transaction Type	Base Current Units	Identifier	Description	Coupon Rate	Final Maturity	Price	Base Amount
02/02/2024	02/02/2024	Buy	14,333.58	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	1.000	-14,333.58
02/09/2024	02/09/2024	Sell	-3,248,286.09	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	1.000	3,248,286.09
02/09/2024	02/09/2024	Cash Transfer	0.00	CCYUSD	US DOLLAR	0.000	02/29/2024	---	-3,248,231.93
02/09/2024	02/09/2024	Cash Transfer	0.00	CCYUSD	US DOLLAR	0.000	02/29/2024	---	-902,991.83
02/09/2024	02/09/2024	Cash Transfer	0.00	CCYUSD	US DOLLAR	0.000	02/29/2024	---	902,991.83
02/22/2024	02/22/2024	Custody Fee	0.00	CCYUSD	US DOLLAR	0.000	02/29/2024	---	-54.16
---	---	---	-3,233,952.51	---	---	---	02/29/2024	---	-14,333.58

Summary

Entry Date	Settle Date	Transaction Type	Base Current Units	Identifier	Description	Coupon Rate	Final Maturity	Price	Base Amount
---	---	---	-3,233,952.51	---	---	---	02/29/2024	---	-10,638.86

* Grouped by: Status. * Groups Sorted by: Status. * Showing transactions with Entry Date within selected date range. * Weighted by: Absolute Value of Base Principal. * MMF transactions are expanded.

* The Transaction Detail/Trading Activity reports provide our most up-to-date transactional details. As such, these reports are subject to change even after the other reports on the website have been locked down. While these reports can be useful tools in understanding recent activity, due to their dynamic nature we do not recommend using them for booking journal entries or reconciliation.

Trading Activity

Base Currency: USD 02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

1145-InVivo Therapeutics (43924)

Dated: 03/05/2024

* Does not Lock Down.

Buy

Trade Date	Settle Date	Transaction Type	Identifier	Description	Coupon Rate	Final Maturity	Base Current Units	Price	Base Principal	Base Accrued Interest	Base Net Total Realized Gain	Base Amount
02/02/2024	02/02/2024	Buy	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	14,333.58	1.000	14,333.58	0.00	0.00	-14,333.58
02/02/2024	02/02/2024	Buy	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	14,333.58	1.000	14,333.58	0.00	0.00	-14,333.58

Sell

Trade Date	Settle Date	Transaction Type	Identifier	Description	Coupon Rate	Final Maturity	Base Current Units	Price	Base Principal	Base Accrued Interest	Base Net Total Realized Gain	Base Amount
02/09/2024	02/09/2024	Sell	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	-3,248,286.09	1.000	-3,248,286.09	0.00	0.00	3,248,286.09
02/09/2024	02/09/2024	Sell	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	-3,248,286.09	1.000	-3,248,286.09	0.00	0.00	3,248,286.09

Summary

Trade Date	Settle Date	Transaction Type	Identifier	Description	Coupon Rate	Final Maturity	Base Current Units	Price	Base Principal	Base Accrued Interest	Base Net Total Realized Gain	Base Amount
---	---	---	61747C707	MORG STAN I LQ:GV I	5.220	02/29/2024	-3,233,952.51	1.000	-3,233,952.51	0.00	0.00	3,233,952.51

* Grouped by: Transaction Type. * Groups Sorted by: Transaction Type. * Showing transactions with Trade Date within selected date range. * Weighted by: Absolute Value of Base Principal. * MMF transactions are expanded.

* The Transaction Detail/Trading Activity reports provide our most up-to-date transactional details. As such, these reports are subject to change even after the other reports on the website have been locked down. While these reports can be useful tools in understanding recent activity, due to their dynamic nature we do not recommend using them for booking journal entries or reconciliation.

Roll Forward

██████████ 1145-InVivo Therapeutics (43924)

Base Currency: USD 02/01/2024 - 02/29/2024

[Return to Table of Contents](#)

Dated: 03/05/2024

Identifier, Description	Beginning Market Value + Accrued, Base Purchases	Base Sales, Base Maturities and Redemptions	Base Paydowns	Base Net Transferred Value	Base Amortization/ Accretion	Change In Accrued Balance	Net Realized Gain/Loss	Base Change In Net Unrealized Gain/Loss	Base Change In Cash, Payables/Receivables	Ending Market Value + Accrued
61747C707 MORG STAN I LQ:GV I	3,233,952.51 14,333.58	-3,248,286.09 0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CCYUSD Receivable	14,333.58 0.00	0.00 0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10,638.86	3,694.72
---	3,248,286.09 14,333.58	-3,248,286.09 0.00	0.00	0.00	0.00	0.00	0.00	0.00	-10,638.86	3,694.72

* Weighted by: Ending Base Market Value + Accrued. * Holdings Displayed by: Lot.

Investment returns and principal value will fluctuate, so that clients' investments when sold may be worth more or less than their original cost. The figures shown are past performance; past performance is no guarantee of future results. The results reflect the deduction of advisory fees and other expenses. The results portrayed also reflect the reinvestment of dividends and other earnings.

Month end reports reflect the net market value of the securities and the balance of FDIC insured products in your account on a trade date basis on the last business day of the accounting period for assets managed by SVB Asset Management. They are presented by SVB Asset Management based on transactional and holdings data provided by U.S. Bank, the account custodian. All other reports are prepared and calculated by Clearwater Analytics, which may include data provided by third parties. We believe the data to be reliable; however, we cannot guarantee its accuracy.

This is a summary of activity in your account for the time period indicated. This summary is not intended for tax reporting purposes. SVB Asset Management does not provide tax or legal advisory services, and no one associated with SVB Asset Management is authorized to render such advice.

3003 Tasman Drive, Santa Clara, CA 95054

February 2024

Reporting Activity 02/01 - 02/29

Page 1 of 2

ADDRESS SERVICE REQUESTED

>049158 5225497 0001 092196 10Z

INVIVO THERAPEUTICS CORPORATION
1500 DISTRICT AVENUE
BURLINGTON, MA 01803

Managing Your Accounts

	Phone:	(408) 654-4636
	Toll-Free:	(800) 774-7390
	Email:	clientsupport@svb.com
	Online:	www.svb.com

Summary of Accounts

Account Type	Account Number	Ending Balance
Collateral MMA	XXXXXX0116	\$50,000.00
Total Balance		\$50,000.00

Collateral MMA - XXXXXX0116

Account Summary

Date	Description	
02/01/2024	Beginning Balance	\$50,000.00
02/29/2024	Ending Balance	\$50,000.00
	Total debits this period	\$0.40
	Total credits this period	\$0.00
	Service Charge	\$0.00

Interest Summary

Description	
Interest Earned From 02/01/2024 Through 02/29/2024	
Annual Percentage Yield Earned	0.01%
Interest Days	29
Interest Earned	\$0.40
Interest Paid This Period	\$0.40
Interest Paid Year-to-Date	\$0.82
Interest Withheld Year-to-Date	\$0.00

Account Activity

Transaction Date	Description	Debits	Credits	Balance
02/01/2024	Beginning Balance			\$50,000.00
02/29/2024	INTEREST PAYMENT	\$0.00	\$0.40	\$50,000.40
02/29/2024	INT TRANSFER TO 3301084583	-\$0.40	\$0.00	\$50,000.00
02/29/2024	Ending Balance			\$50,000.00

Interest Rate Summary

Date	Rate
02/01/2024	0.01%

CHECKS OUTSTANDING									CHECKBOOK RECONCILIATION		
DATE OR #	AMOUNT		DATE OR #	AMOUNT		DATE OR #	AMOUNT				
									ENTER BALANCE THIS STATEMENT	\$	
									ADD		
									RECENT DEPOSITS (NOT CREDITED ON THIS STATEMENT)	\$	
									SUBTOTAL	\$	
									SUBTRACT TOTAL ITEMS OUTSTANDING	\$	
BALANCE should agree with your checkbook balance after deducting charges and adding credits not shown in your checkbook but included on this statement as follows: Interest-ADD Overdraft-DEDUCT Automatic Payment-DEDUCT Automatic Advance-ADD Service Charge-DEDUCT									BALANCE	\$	

PLEASE REPORT ANY ERRORS OR OMISSIONS PROMPTLY TO US. ERRORS OR OMISSIONS THAT ARE REPORTED WITHIN THE FIRST 30 DAYS FROM THE DATE OF THE LAST STATEMENT CYCLE ARE USUALLY RESOLVED MUCH MORE QUICKLY THAN DATED REQUESTS. As a fraud prevention measure, you need to review your statements and report unauthorized use or errors to us, as explained in more detail below.

If your checkbook and statement do not balance have you:

- ☐ Accounted for bank charges? ☐ Verified additions and subtractions in your checkbook? ☐ Compared canceled checks to check stub? ☐ Compared deposit amounts on statement to your checkbook?

Any charges for imprinted checks include state sales tax computed at the current rate, when applicable. You can call (800) 774-7390 to request an item or substitute check, or a legible copy. We will without charge provide at least two items (or substitute checks or legible copies) upon request, with respect to each statement.

IN CASE OF ERRORS OR QUESTIONS CONCERNING YOUR ELECTRONIC TRANSFERS
(For Consumer Clients)

Telephone Silicon Valley Bank at (800) 774-7390 or write us at: Silicon Valley Bank, Attn: Client Services, 3003 Tasman Drive, Santa Clara, CA 95054, as soon as you can, if you think your statement or your receipt is wrong or if you need more information about a transfer on the statement or receipt. We must hear from you no later than 60 days after we sent you the FIRST statement on which the error or problem appeared.

- Tell us your name and account number (if any).
- Describe the error or the transfer you are unsure about, and explain as clearly as you can why you believe this is an error or why you need more information.
- Tell us the dollar amount of the suspected error.

We will investigate your complaint and will correct any error promptly. If we take more than 10 business days to do this, we will credit your account for the amount you think is in error, so that you will have the use of the money during the time it takes us to complete our investigation.

For questions about preauthorized transfers, please contact us at (800) 774-7390.

IN CASE OF UNAUTHORIZED USE OF YOUR CHECKS OR ACCOUNTS

You agree to review your statement and to report unauthorized use (checks or other charges that are forged, altered or other unauthorized use) or error immediately. Your deposit agreement sets specific times within which you must report unauthorized use or errors to us. In summary (and subject to special rules that may apply to consumers), if you fail to report unauthorized use or errors to us within 30 days after your statement is available, you may be liable for subsequent unauthorized use by the same wrongdoer. If you fail to report within 60 days, you may also be precluded from asserting the unauthorized use or other error against us. Your statement is deemed "available" when made available in paper or electronic form. Your deposit agreement or Related Agreements may set shorter reporting requirements, such as for ACH services.

FAIR CREDIT REPORTING ACT

We may report information about your account to credit bureaus. Late payments, missed payments, or other defaults on your account may be reflected in your credit report.